LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...
MADISON, N.J., March 20, 2026--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of ...
InflaRx was founded in 2007 and maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan. In other recent news, InflaRx N.V. has disclosed post-hoc analyses indicating potential efficacy ...
Dr. Clarissa Souza, a board-certified veterinary dermatologist and head of the dermatology and otology service at the University of Illinois Veterinary Teaching Hospital in Urbana. Dr. Clarissa Souza, ...
Please provide your email address to receive an email when new articles are posted on . There are few medications dermatologists can prescribe for pyoderma gangrenosum, a complex wound disease.
Vanda Pharmaceuticals Inc. (Vanda), a leading global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application ...
A Prescription Drug User Fee Act target date of December 12, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics ...
InflaRx N.V. (NASDAQ: IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...
Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...
1 Department of Cardio Thoracic and Vascular Surgery, All India Institute of Medical Sciences, Raipur, India. 2 Department of Cardio Thoracic and Vascular Surgery, Sri Padmavathi Children’s Heart ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results